Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $23.57 Consensus Target Price from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $23.43.

A number of analysts have weighed in on the company. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Bank of America cut their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday. StockNews.com cut shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Finally, Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th.

Remove Ads

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.55% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the company. Private Advisor Group LLC lifted its stake in Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Private Advisor Group LLC now owns 26,104 shares of the company's stock worth $470,000 after purchasing an additional 2,990 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 273.5% in the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company's stock worth $82,000 after buying an additional 3,323 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Teva Pharmaceutical Industries by 1.3% during the third quarter. Janney Montgomery Scott LLC now owns 1,400,325 shares of the company's stock valued at $25,234,000 after buying an additional 17,545 shares during the period. Van ECK Associates Corp grew its position in Teva Pharmaceutical Industries by 12.5% during the third quarter. Van ECK Associates Corp now owns 1,875,387 shares of the company's stock worth $34,526,000 after buying an additional 208,673 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in Teva Pharmaceutical Industries by 73.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 465,032 shares of the company's stock worth $8,380,000 after acquiring an additional 197,585 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 0.1 %

NYSE:TEVA traded down $0.01 during trading hours on Tuesday, hitting $15.34. 11,313,904 shares of the company were exchanged, compared to its average volume of 12,767,607. The company has a fifty day simple moving average of $19.00 and a 200 day simple moving average of $18.40. Teva Pharmaceutical Industries has a one year low of $12.51 and a one year high of $22.80. The stock has a market capitalization of $17.40 billion, a price-to-earnings ratio of -10.58, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.